NAD+ 500 mg: Core Biology Does Not Equal Proven Infusion Benefit

Reviewed for accuracy by the Gorilla Research Insights research team · 2026-07-04

CELLULAR METABOLISM NAD+ 500 mg: Core Biology Does Not Equal Proven Infusion Benefit NAD+ is indispensable to redox chemistry and enzyme systems involved in metabolism and DNA-damage responses. The importance of the molecule inside cells does not by itself establish what an externally administered 500 mg material does in people.

What is established

NAD+ cycles between oxidized and reduced states and serves as a substrate for enzymes including sirtuins and PARPs. Human trials with NAD+ precursors show that some precursors can raise measured NAD-related metabolites ^[1], but precursor studies are not trials of intravenous NAD+.

Direct evidence

A small pilot study followed plasma and urine metabolites during a six-hour intravenous NAD+ infusion and primarily addressed metabolism and excretion ^[2]. It did not establish anti-aging, cognitive, recovery, addiction, or performance outcomes. A 2026 retrospective commercial-clinic comparison reported infusion symptoms and short follow-up; its nonrandomized design limits causal conclusions ^[3]. The “500 mg” label is a vial quantity, not an evidence grade. It does not demonstrate cellular uptake, bioavailability in a target tissue, or equivalence to a study preparation.

Research priorities

Controlled studies need to define disposition of intact NAD+, relevant metabolites, target engagement, adverse events, and prespecified clinical endpoints. Until then, strong wellness claims exceed the direct evidence.

Primary sources

• ^[1] Martens et al. Randomized nicotinamide-riboside trial in older adults . • ^[2] Grant et al. Human plasma and urine NAD+ metabolome during intravenous infusion . • ^[3] Reyna et al. Retrospective IV NAD+ versus IV NR tolerability pilot . Educational material only. It does not provide dosing or use advice.